# MONARCH 3 (NCT02246621)

> A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02246621
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Eli Lilly and Company
- Conditions: Breast Cancer
- Interventions: Abemaciclib; Anastrozole; Letrozole; Placebo
- Enrollment: 493
- Primary outcome: Progression Free Survival (PFS)

## Commentary we found

- YouTube: 69
- Podcasts: 51
- X threads: 31

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=monarch-3-nct02246621

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02246621", "email": "<work email>"}; the inbox owner confirms by the emailed link.